Actively Recruiting
Randomized, Double-Blind Study to Assess EDI048s Safety and Efficacy in Healthy Adults with Experimental Cryptosporidium Infection
Led by Novartis Pharmaceuticals · Updated on 2026-08-19
80
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying cryptosporidiosis, a parasitic infection, by evaluating the potential benefits of a new drug called EDI048. The study is a phase 2 clinical trial involving healthy adult volunteers who are deliberately exposed to Cryptosporidium parvum oocysts ABO809 to induce symptoms. The purpose is to assess whether EDI048 can improve clinical signs and symptoms of cryptosporidiosis and support its use in children with this infection. Participants will first receive a single oral dose of ABO809 to cause cryptosporidiosis symptoms. Those who develop symptoms will then be randomly assigned to receive either EDI048 or a placebo, administered orally, in a blinded manner. This parallel-group, placebo-controlled study compares the effects of EDI048 against placebo in symptomatic adults. During the study, participants will be closely monitored for symptoms and stool characteristics, with measurements including stool grades on days 3 to 5 after treatment starts. Other assessments include gastrointestinal symptoms, diarrheal episodes, stool weight, and presence of the parasite in fecal samples up to day 35. Pharmacokinetics of EDI048 and safety events will also be tracked. The trial includes regular clinical evaluations, laboratory tests, and questionnaires to evaluate the drugs safety, tolerability, and efficacy over the study period.
CONDITIONS
Brief Title
Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here